Norway· NO-ID_E53D0859-1345-4DAA-AD75-3A5BA7AAC020
Esperoct
A coagulation factor viii product containing turoctocog alfa pegol, registered in Norway by Novo Nordisk A/S (2). The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Coagulation factor viii is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Coagulation factor viii · ATC B02BD02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Turoctocog Alfa Pegol
- Manufacturer
- Novo Nordisk A/S (2)
- Country
- Norway (NO)
- ATC code
- B02BD02
- ATC class
- Coagulation factor VIII
- Defined daily dose
- 1 TSD, E
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_varenummer4890881NOK 26029.4
- no_merkevare_idID_E53D0859-1345-4DAA-AD75-3A5BA7AAC020
- gtin5712249111632
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for coagulation factor viii.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor viii · interactions on record
4 records
- 2 severe
- 2 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- EmicizumabB02BX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor viii in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEsperoct 3000 IUNovo Nordisk
- SpainESPEROCT 3000 UI POLVO Y DISOLVENTE PARA SOLUCION INYECTABLENovo Nordisk A/S
- SwedenEsperoct 3000 IE Pulver och vätska till injektionsvätska, lösningNovo Nordisk A/S
- FinlandEsperoctNovo Nordisk A/S
- SwitzerlandEsperoct
- CzechiaESPEROCTNovo Nordisk A/S, Bagsvaerd
- IrelandEsperoct 1000 IU Powder and solvent for solution for injectionNovo Nordisk A/S
- IcelandEsperoctNovo Nordisk A/S*
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Iceland · Esperoct
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/00c5e064-6672-4f91-ab9f-491eaee027a6 GET /v1/drugs/00c5e064-6672-4f91-ab9f-491eaee027a6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver og væske til injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Koagulasjonsfaktor VIII",
"merkevare_id": "ID_E53D0859-1345-4DAA-AD75-3A5BA7AAC020",
"name_form_strength": "Esperoct pulv+væske til inj oppl 3000 IE",
"prescription_group": "C"
}See everything about coagulation factor viii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.